The Global Popularity of COVID-19 and the Possibility of Fungal Co-infections {#Sec1}
=============================================================================

As the human-to-human transmitted disease, coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been an emergency global public health events \[[@CR1], [@CR2]\]. Till May 18th, 2020, the COVID-19 has rapidly spread to 212 countries and caused nearly 5 million laboratory-confirmed cases and more than 310,000 deaths globally. Like SARS-CoV and Middle East Respiratory Syndrome Coronavirus (MERS-CoV), SARS-CoV-2 is responsible for lower respiratory infection and can cause Acute Respiratory Distress Syndromes (ARDS) \[[@CR3]\]. Besides, the diffuse alveolar damage with severe inflammatory exudation, COVID-19 patients always have immunosuppression with a decrease in CD4 + T and CD8 + T cells \[[@CR4]\]. Critically ill patients, especially the patients who were admitted to the intensive care unit (ICU) and required mechanical ventilation, or had a longer duration of hospital stays, even as long as 50 days, were more likely to develop fungal co-infections \[[@CR5]\]. Hence, it is important to notice that COVID-19 patients can develop further fungal infections during the middle and latter stages of this disease, especially severely ill ones \[[@CR6]\].

Epidemiology of Fungal Co-infections in COVID-19 Patients {#Sec2}
=========================================================

To analyze the incidence of fungal co-infections in COVID-19 patients, we searched PubMed, Scopus, Embase, and Web of Science, using the keywords "fungi" OR "fungus" OR "fungal infection" OR "invasive fungal diseases" OR "secondary infection" AND "COVID-19" OR "SARS-CoV-2" OR "2019-nCoV" OR "2019 novel coronavirus" without date (up to May 18, 2020) and language restrictions. We also searched CNKI and Wanfang Data using the same terms in Chinese, with no time restrictions. The title, abstract, and full text of related articles determined according to these search criteria were carefully reviewed by the authors. Unfortunately, we have found very few articles reporting on fungal co-infections, not only that, some studies have not provided the details of the pathogens. Even so, we found COVID-19 patients, especially severely ill ones or accompanied with immunocompromised state, had co-infections of fungi \[[@CR7]\]. In China, Chen et al. performed fungal culture on all 99 COVID-19 patients at admission and found five (5%, 5/99) cases of fungal infection, including one case of *Aspergillus flavus*, one case of *Candida glabrata* and three cases of *C. albicans* \[[@CR8]\]. Yang et al. found there (3/52, 5.8%) patients had fungal co-infection in 52 critically ill patients, including *A. flavus*, *A. fumigatus* and *C. albicans* \[[@CR5]\]. Other China studies have found a higher percentage of secondary infections (8--15%) in COVID-19 patients, but it is not clear whether it is bacterial or fungal infection \[[@CR9], [@CR10]\]. In addition, one study mentioned that 2.8% (31/1099) patients were treated with antifungal medicine, including 1.9% (18/926) non-severe patients and 7.5% (13/173) severe patients, but there was no etiological evidence of fungal co-infection \[[@CR11]\]. Another study mentioned there was no patient treated with antifungal medicine in 149 cases \[[@CR4]\]. A German study found COVID-19 associated invasive pulmonary aspergillosis (IPA) was found in five (26.3%) of 19 consecutive critically ill patients with moderate to severe ARDS \[[@CR12]\]. In Netherlands, there were six patients (19.4%) presumed IPA in 31 ICU patients, of which five were identified *A. fumigatus* \[[@CR13]\]. Besides, among the 5 first well-described French COVID-19 patients, an old severely ill man was co-infected with *A. flavus* by tracheal aspirates culture \[[@CR14]\].

Neglected Fungal Co-infection in COVID-19 Patients by Suggestive Ideas from SARS and Influenza {#Sec3}
==============================================================================================

Studies have shown that SARS-CoV and SARS-CoV-2 belong to the same species and have the similar prevalence, biological and clinical characteristics \[[@CR15]\]. Looking back on SARS in 2003, we found the incidence of fungal infection in SARS patients was 14.8--27%, which was even higher in severely ill ones, up to 21.9--33% \[[@CR16], [@CR17]\], meanwhile, fungal infection was the main cause of death for SARS patients, accounting for 25--73.7% in all causes of death \[[@CR18]\]. Besides, in the past decade, increasing reports of severe influenza pneumonia resulting in ARDS complicated by fungal infection were published \[[@CR19]\]. One research found IPA was diagnosed in 83 (19%) of 432 patients admitted with influenza, which was higher in immunocompromised patients (32%), and in the event of IPA, the mortality will increase from 28 to 51% \[[@CR20]\]. However, as for fungal co-infection in COVID-19 patients, only few studies have reported it, which may have been neglected. Clinically, many COVID-19 patients did not undergo sputum fungal assessment at the beginning, moreover, it is difficult to detect fungus with a single sputum fungal culture \[[@CR11]\]. With the disease aggravating, it is easy to attribute the severe respiratory symptoms to COVID-19, at the most considering of the co-infection with bacterium or even mycoplasma \[[@CR21]\] which usually leads to the in-time use of antibiotics, while the diagnosis of fungal infection is always delayed or neglected. Based on the experience of SARS in 2003 and the cases of invasive aspergillosis combined with severe influenza, it is critically important to pay attention to the probability of COVID-19 accompanied by fungal infections.

Clinical and Diagnostic Perspective of COVID-19 Associated with Fungal Co-infections {#Sec4}
====================================================================================

As the ongoing COVID-19 pandemic, more and more experts are aware of fungal co-infections. The French High Council for Public Health recommended to systematically screen for fungal pathogens in COVID-19 patients \[[@CR6]\]. Lanjuan Li academician and her colleagues who have accumulated experience with severe COVID-19 treatment, reminded clinicians should focus on patients' fungal infections, especially severely ill or immunocompromised ones \[[@CR22]\]. At the early phase of the disease or with extrapulmonary fungal infections, it may present with atypical chest imaging. Hence, it is necessary for severely ill patients to receive fungal pathogens surveillance, including (i) etiological examination: direct microscopy and culture; (ii) histopathology; (iii) serology: antigen and antibody, (1,3)-*β*-[d]{.smallcaps}-glucan (BDG) \[[@CR23]\] and galactomannan (GM) detection by serum are also need to be tested for suspicious patients, while bronchoalveolar lavage fluid (BALF) and tracheal aspirate (TA) sampling for culture and biomarker testing should be performed under well-protected conditions due to the risk of aerosol spreading and health care worker infections \[[@CR24]\]; (iv) PCR-based methods: Real-time polymerase chain reaction (PCR) techniques and molecular identification can be performed to identify pathogens if necessary \[[@CR25]\]. After identifying the pathogen, the antifungal susceptibility testing (AST) can be performed to select sensitive antifungal drugs. If the AST cannot be carried out, it should be treated empirically. The main fungal pathogens for fungal co-infections in severe COVID-19 patients are *Aspergillus* and *Candida.* Other infrequent opportunistic pathogenic fungus caused lung infections also need to be considered, such as *Mucor* and *Cryptococcus*.

Invasive Aspergillosis (IA) {#Sec5}
---------------------------

*Aspergillus* species could be an important cause of life-threatening infection in COVID-19 patients, especially in those with high risk factors. The potential risk factors for the patients include GC use, prolonged neutropenia, chronic obstructive pulmonary disease (COPD), allogeneic hematopoietic stem cell transplant (allo-HSCT) \[[@CR26]\], solid organ transplant (SOT) \[[@CR27]\], inherited immunodeficiencies, hemopoietic malignancy (HM), cystic fibrosis (CF) \[[@CR28]\], etc. The diagnosis of IA requires a microbiologic and/or histopathologic evidence, although specimen acquisition is challenging in many patients because lung biopsy might be contraindicated in patients with coagulation disorders or severe respiratory failure \[[@CR13]\]. Histopathologic examination mainly rely on finding special fungal stains on lung fluid or tissue when a fungal infection is suspected and may reveal the characteristic acute angle branching septate hyphae of *Aspergillus* spp., and Grocott-Gomori's methenamine-silver stain (GMS) and periodic acid-Schiff (PAS) stains of fixed tissue will helpful, while it is difficult to distinguish *Aspergillus* spp. from other filamentous fungi such as *Fusarium* spp. and *Scedosporium* spp. \[[@CR29]\]. Therefore, it is necessary to have a definitive confirmation by culture or nonculture technique, including (i) direct microscopic examination with the optical brightener methods, Calcofluor or Blankophor, which may increase the sensitivity and specificity for detecting *Aspergillus*-like features; (ii) culture on fungal-specific media at 37 °C for 2--5 days, if positive, morphological features of *Aspergillus* can be identified under the microscope or the DNA sequencing may be used in reference laboratories to identify the species accurately, but usually culture yield is low and a negative result does not exclude the diagnosis of IA; (iii) molecular assays targeting ribosomal DNA (rDNA) sequences can also be used for detection of *Aspergillus* in tissues or BALF, especially PCR-based assays can be used to detect *Aspergillus* spp. and CYP51A resistance mutations in *A. fumigatus*, although these methods have not been standardized or limited by laboratory conditions or proven commercial reagents in some countries \[[@CR30]\]; (iv) serum and BALF GM testing are also recommended as an early and accurate marker using less invasive techniques for the diagnosis, especially in neutropenic patients, with advantages of less injury and time-efficient, though sometimes this test in blood samples are less sensitive than cultures of respiratory samples \[[@CR25]\].

The treatment recommendations can be supported by the 2016 Update guideline by the Infectious Diseases Society of America that the prophylaxis, therapeutic medication, combined, and alternative medication of *aspergillus* infection have been given more detailed guidance opinions \[[@CR30]\]. Generally, drugs recommended for the treatment and prophylaxis of IA include triazoles (itraconazole, voriconazole, posaconazole, esaconazole), Amphotericin B and its liposomes and echinococcins (micafungin or carpofenjing). Most patients can choose triazole drugs to treat IA, however, therapeutic drug monitoring (TDM) is recommended and the interaction between azoles and other drugs should be fully considered.

Invasive Candidiasis (IC) {#Sec6}
-------------------------

For the severe COVID-19 patients who have more opportunities to be treat with broad-spectrum antibacterial drugs, parenteral nutrition and invasive examinations, or the patients accompanied with prolonged neutropenia and other immune impairment factors, the risk of infection with *Candida* species may significantly increase \[[@CR31]\]. Diagnosis of IC depends on culture methods including culture of blood or other samples collected under sterile conditions which are usually considered as gold standards for IC, and nonculture diagnostic tests including mannan and antimannan IgG tests, *C. albicans* germ tube antibody (CAGTA), BDG and PCR-based assays, which are now entering clinical practice as adjuncts to cultures \[[@CR32]\]. There are mainly two disadvantages about blood culture, on the one hand, the blood culture time is long, because the average positive alarm time is 2--3 days (range 1 to ≥ 7 days), plus identification and susceptibility test duration 4 to 6 days, on the other hand, it is not sensitive than PCR with much lower detection limit when *Candida* concentration is ≤ 1 CFU/mL and easy to have failure to detect in extremely low concentrations of candidiasis, intermittent candidiasis or deep *Candida* infection has not entered the blood. Hence, several nonculture diagnostic tests are recommended, but also there is widespread uncertainty about their utility in clinical practice \[[@CR31]\]. BDG is a major cell wall constituent of *Candida* and most pathogenic fungi, excluding *Cryptococcus* species, *Blastomyces* species, and *Mucorales*, which is widely used in clinical and well recommended by detecting serum, but cannot distinguish between *Candida* and other fungi \[[@CR25]\]. Besides, mannan and antimannan IgG tests, CAGTA are employed at many European centers, and higher sensitivity and specificity by a combination with mannan/antimannan assay are observed \[[@CR33]\]. There are promising PCR tests, including multiplex-PCR platforms, at the same time, it exists some limitations for a lack of multicenter validation of assay performance, so there are no FDA-cleared PCR assays for *Candida*, but commercial and in-house tests are widely available. Further, T2 magnetic resonance is also can be used by amplifying and detecting *Candida* DNA, but its feasibility in early diagnosis of candidemia remains unclear. MALDI-TOF technology is available in more hospitals with the biggest advantage of its promptness taking no more than 5 min to identify a microorganism from isolated colonies, even researchers have developed protocols to identify yeasts directly from positive blood culture bottles within half an hour without performing a subculture \[[@CR32]\]. Overall, not only it is necessary to fully realize the benefits of combining culture and nonculture methods, but also, clinicians must take the types of IC, the strengths and limitations of each assay and the context of the clinical setting into account to have a judicious interpretation. Besides, susceptibility test is recommended for all blood-stream and other clinically relevant *Candida* isolates, especially for *C. glabrata* or *C. parapsilosis.*

The treatment recommendations can be supported by the 2016 Update guideline by the Infectious Diseases Society of America that the therapeutic and alternative medication of candidiasis infection have been given more detailed guidance opinions \[[@CR34]\]. Generally, patients who are suspected or confirmed with IC should be treated with echinocandin (caspofungin, micafungin, and anidulafungin), azoles (fluconazole, voriconazole, itraconazole), and Amphotericin B and its liposomes, what's more, TDM for azoles should be used to optimize efficacy and limit toxicity.

Invasive Mucormycosis {#Sec7}
---------------------

COVID-19 patients with trauma, diabetes mellitus, GC use, HM, prolonged neutropenia, allo-HSCT, SOT are more likely to develop mucormycosis \[[@CR35]\]. Mucormycosis is usually suspected based on results of direct microscopy or plus fluorescent brighteners from clinical specimens such as sputum, BALF, and skin lesions that *Mucorales* hyphae are non-septate or pauci-septatethe with a variable width of 6--16 μm. To confirm the diagnosis, non-pigmented hyphae showing tissue invasion should be shown in tissue sections stained with hematoxylin--eosin (HE), PAS, or GMS \[[@CR36]\]. Culture of specimens is strongly recommended for identification of genus and species, also AST. What's more, it is suggested to be cultured at 30 °C and 37 °C separately that typically cottony white or grayish black colony usually will be found, afterward morphological identification of fungi or DNA sequencing based on bar code genes, such as 18S, ITS, 28 s, or rDNA. MALDI-TOF identification is just moderately supported because it depends mainly on in-house databases, and many laboratories do not have this capacity \[[@CR37]\]. Further, it is promising to detect fungi DNA, in serum as well as in other body fluids, even in paraffin-embedded tissue, however, because of lack of standardization supported it is only with moderate strength.

The treatment recommendations can be supported by the global guideline for the diagnosis and management of mucormycosis in 2019 by European Confederation of Medical Mycology (ECMM) and Mycoses Study Group Education and Research Consortium that the therapeutic and alternative medication of mucormycosis have been given more detailed guidance opinions \[[@CR35]\]. Generally, it strongly supports an early complete surgical treatment for mucormycosis whenever possible, in addition to systemic antifungal treatment. In neutropenic patients, those with graft-versus-host disease or high risk factor, primary prophylaxis with posaconazole may be recommended. Amphotericin B lipid complex, liposomal Amphotericin B and posaconazole oral suspension are treated as the first-line antifungal monotherapy, while isavuconazole is strongly supported as salvage treatment. There are no convincing data to guide the use of antifungal combination therapy of polyenes and azoles or polyenes plus echinocandins.

Invasive Cryptococcosis {#Sec8}
-----------------------

COVID-19 patients with human immunodeficiency virus (HIV) infection accompanied by CD4 + T-lymphocyte count \< 200 cells/μL, allo-HSCT, SOT, or other immune impaired are susceptible to cryptococcosis which predominantly present as meningoencephalitis \[[@CR38]\]. Given the complexities surrounding the diagnosis of cryptococcosis and identification of *Cryptococcus* species including *C. neoformans* and *C. gattii* species, the diagnosis of cryptococcosis is usually based on a combination of clinical and laboratory confirmation. The methods used to confirm the infection are culture, direct microscopy, histopathology, serology, and molecular detection. To diagnose cryptococcosis, specimen from cerebrospinal fluid (CSF) can be mixed with India ink and observed under a microscope that the distinctive structure for *Cryptococcus* spp. with narrow budding encapsulated yeasts usually can be found. Samples for culture should be placed on Sabouraud dextrose agar at 30 °C for 7 days, in aerobic conditions, and observed daily. Moreover, cultures from patients receiving systemic antifungal therapy might need longer to grow. *Cryptococcus* appears as mucoid creamy colonies. Capsular polysaccharides of *Cryptococcus* can be detected and quantified from body fluids such as serum, CSF, BAL, or pathological tissue. Three formats of cryptococcal antigen (CrAg) detection tests are currently available: the latex agglutination test (LAT), the enzyme-linked immunoassay (EIA), and the lateral flow immunoassay (LFA). These methods are rapid, sensitive, and specific, but have not been standardized for respiratory specimens such as BAL, pleural fluid, or sputum \[[@CR32]\]. Molecular detection of *Cryptococcus* is required in specific situations where other diagnostic tools have failed to confirm a diagnosis of cryptococcosis. These molecular methods include pan-fungal PCR, DNA sequencing for identification, multiplex PCR, isothermal amplification method, and probe-based microarrays. Once a diagnosis cryptococcosis is made, a lumbar puncture and cerebrospinal fluid (CSF) examination (including antigen) are recommended in all patients \[[@CR39]\]. *Cryptococcus* can disseminate into the central nervous system causing cryptococcal meningitis.

The treatment recommendations can be supported by guidelines for the diagnosis, prevention, and management of cryptococcal disease in HIV-infected adults, adolescents, and children in 2018 by World Health Organization (from: <https://www.who.int/hiv/pub/guidelines/cryptococcal-disease/en/>). Generally, the following is recommended as the preferred regimen: (i) Induction phase for amphotericin B deoxycholate and + flucytosine, followed by fluconazole; alternative options for fluconazole + flucytosine or amphotericin B deoxycholate + fluconazole. (ii) Consolidation phase for fluconazole. (iii) Maintenance (or secondary prophylaxis) phase for fluconazole.

Summary {#Sec9}
=======

By analyzing retrospective analysis of SARS and influenza data from China and worldwide, we surmise that the fungal co-infections associated with global COVID-19 might be missed or misdiagnosed. Further, as a life-threatening infectious disease, COVID-19 patients showed overexpression of inflammatory cytokines, and impaired cell-mediated immune response with decreased CD4 + T and CD8 + T cell counts, indicating its susceptibility to fungal co-infection. Moreover, COVID-19 patients accompanied with immunocompromised state, such as prolonged neutropenia, HSCT, GC use, SOT, inherited or acquired immunodeficiencies, and tumor are more likely to develop fungal co-infection. Here, we summarized updated diagnostic information (histopathology, direct microscopic examination, culture, (1,3)-*β*-[d]{.smallcaps}-glucan, galactomannan, PCR-based assays, MALDI-TOF technology, etc.) and treatment recommendations of invasive mycosis. We suggest it is prudent to assess the risk factors, the types of invasive mycosis, the strengths and limitations of diagnostic methods, clinical settings, and the need for standard or individualized treatment in COVID-19 patients. Finally, provide a clinical flow diagram (Fig. [1](#Fig1){ref-type="fig"}) to assist the clinicians and laboratory experts in the management of aspergillosis, candidiasis, mucormycosis, or cryptococcosis as comorbidities in COVID-19 patients.Fig. 1Diagnostic and therapeutic pathway for invasive fungal co-infection
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